Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 4

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 4
---
 our private placement offering that closed on February 26, 2025 (the “Warrant                         
 Exercise Proposal”)                                                                                                                               |     | FOR                       |     |             24 |
| Approval of an increase in the authorized number of shares of Common Stock                                                                        
 from 100,000,000 to 350,000,000 (the “Authorized Increase Proposal”)                                                                              |     | FOR                       |     |             26 |
| Approval                                                                                                                                          
 of an anti-dilution provision of the Common Stock purchase warrants issued in connection                                                          
 with our public offering that closed on May 7, 2025 (the “May 2025 Warrants”),                                                                    
 and the reduction in exercise price of the May 2025 Warrants (subject to a floor price of                                                         
 $0.10 per share) and corresponding increase in the number of shares issuable upon exercise                                                        
 thereof of up to an aggregate maximum of 49,907,811 shares of our Common Stock, resulting                                                         
 from the triggering of such anti-dilution provision (the “Anti-Dilution Adjustment                                                                
 Proposal”)                                                                                                                                        |     | FOR                       |     |             27 |
| Approval                                                                                                                                          
 of an adjournment of the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of                  
 proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split              
 Proposal, the Warrant Exercise Proposal, the Authorized Increase Proposal, and/or the Anti-Dilution Adjustment Proposal                           |     | FOR                       |     |             29 |

In addition to these matters, stockholders may be
asked to vote on such other business as may properly come before the Annual Meeting.

Even if you plan to attend the Annual Meeting, please vote in advance so that your vote will be counted if you later decide not to attend the Annual Meeting.

| 1 |

<div align='center'>QUESTIONS AND ANSWERS ABOUT

THE PROXY MATERIALS AND THE ANNUAL MEETING</div>

Who is soliciting my vote?

The Board of Directors
of bioAffinity Technologies, Inc. is soliciting your proxy to be used at the Annual Meeting.

Why did I receive a one-page Notice in the mail regarding the internet availability of proxy materials this year instead of a full set of proxy materials?

Pursuant to rules adopted by the Securities
and Exchange Commission (the “SEC”), we have elected to mail to our stockholders a Notice